Compare PRPO & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRPO | SILO |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Apparel |
| Sector | Industrials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.1M | 379.7K |
| IPO Year | 2000 | 2011 |
| Metric | PRPO | SILO |
|---|---|---|
| Price | $24.25 | $6.76 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 18.5K | ★ 75.8K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.15 | 57.98 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $24,049,000.00 | $72,102.00 |
| Revenue This Year | N/A | $1.86 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 29.77 | N/A |
| 52 Week Low | $13.02 | $0.22 |
| 52 Week High | $33.63 | $6.78 |
| Indicator | PRPO | SILO |
|---|---|---|
| Relative Strength Index (RSI) | 59.59 | 72.19 |
| Support Level | $22.32 | $0.35 |
| Resistance Level | $25.70 | N/A |
| Average True Range (ATR) | 1.69 | 0.58 |
| MACD | 0.45 | -0.17 |
| Stochastic Oscillator | 85.33 | 99.28 |
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.